Enhanced tumor detection in the presence of fatty liver disease: Cell‐specific contrast agents

It is assumed that hepatobiliary, cell‐specific contrast agents will be adversely affected by the presence of diffuse liver disease. The diagnostic efficacy for tumor detection in the presence of fatty liver disease was experimentally studied at contrast‐enhanced magnetic resonance (MR) imaging with manganese‐DPDP (N,N′‐dipyridoxylethylenediamine‐N,N′‐diacetate 5,5′‐bis[phosphate]) and gadobenate dimeglumine (Gd‐BOPTA/dimeg) and compared with conventional and chemical shift imaging. Carcinosarcoma was implanted into the liver of rats, and fatty liver was induced with L‐ethionine. Without contrast agents, the tumor‐fatty liver contrast‐to‐noise ratio (C/N) was increased on T1‐weighted and decreased on T2‐weighted MR images relative to tumor‐bearing control rats without fatty liver. Chemical shift imaging (phase‐contrast method) increased the tumor—fatty liver C/N from 2.3 ± 1.0 to 6.1 ± 1.7 (P <.001). Mn‐DPDP and Gd‐BOPTA/dimeg increased the tumor—fatty liver C/N from ‐5.4 ± 1.6 to ‐11.0 ± 1.9 and −9.8 ± 3.4, respectively (P <.001). The hepatobiliary, cell‐specific contrast agents were equally effective in both fatty and nonfatty liver and outperformed both chemical shift and conventional MR imaging in detecting liver tumors.